Cancer treatment and survivorship statistics, 2022
Статистика лечения рака и выживаемости пациентов после лечения, 2022 год
2022-06-23
SCID: 54.1/be94s749
Discuss with AI
National Cancer DatabaseSurveillance, Epidemiology, and End Resultscancer prevalencecancer survivorshipracial disparities in treatment
Figures from the paper
Abstract (AI)
The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics, and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Database are presented for the most prevalent cancer types by race, and cancer-related and treatment-related side-effects are also briefly described. More than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. The 3 most prevalent cancers are prostate (3,523,230), melanoma of the skin (760,640), and colon and rectum (726,450) among males and breast (4,055,770), uterine corpus (891,560), and thyroid (823,800) among females. More than one-half (53%) of survivors were diagnosed within the past 10 years, and two-thirds (67%) were aged 65 years or older. One of the largest racial disparities in treatment is for rectal cancer, for which 41% of Black patients with stage I disease receive proctectomy or proctocolectomy compared to 66% of White patients. Surgical receipt is also substantially lower among Black patients with non-small cell lung cancer, 49% for stages I-II and 16% for stage III versus 55% and 22% for White patients, respectively. These treatment disparities are exacerbated by the fact that Black patients continue to be less likely to be diagnosed with stage I disease than White patients for most cancers, with some of the largest disparities for female breast (53% vs 68%) and endometrial (59% vs 73%). Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based strategies and equitable access to available resources are needed to mitigate disparities for communities of color and optimize care for people with a history of cancer. CA Cancer J Clin. 2022;72:409-436.
Key Findings
1
Among males, prostate, melanoma of the skin, and colorectal cancers were the three most prevalent; among females, breast, uterine corpus, and thyroid cancers predominated.
2
Fifty-three percent of cancer survivors were diagnosed within the previous 10 years, and 67% were aged 65 years or older.
3
For non-small cell lung cancer, surgical treatment was lower among Black than White patients at stages I-II (49% versus 55%) and stage III (16% versus 22%), alongside lower stage I diagnosis rates for Black patients in several cancers.
4
More than 18 million Americans with a history of cancer were alive on January 1, 2022, including 8.3 million males and 9.7 million females.
5
Substantial racial disparities in treatment were observed: 41% of Black patients versus 66% of White patients with stage I rectal cancer received proctectomy or proctocolectomy.
Research Object
Cancer survivors and cancer patients in the United States
Research Subject
Cancer prevalence, treatment patterns, survivorship, treatment-related side effects, and racial disparities in cancer care
Publication Details
Publication Date
2022-06-23
Journal
Publisher
ISSN
Cited by
3605
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Cancer Statistics, 20212021
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer2015
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation2011
Pembrolizumab versus Ipilimumab in Advanced Melanoma2015
American Cancer Society nutrition and physical activity guideline for cancer survivors2022
Cited by4
Cancer treatment and survivorship statistics, 20252025
Developing national cancer survivorship standards to inform quality of care in the United States using a consensus approach2024
Myths and Presumptions About Cancer Survivorship2023
Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles2025